Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound. Continue reading View comments
- Supported exchanges /
- STU /
- NOVA.STU
Novo Nordisk A/S (NOVA STU) stock market data APIs
€100.5
0(0%)
as of November 28, 2024
Price chart is built with Anychart
Novo Nordisk A/S Financial Data Overview
| 100.5 | |
| 100.5 | |
| - | |
| 101 | |
| 99.6 | |
| 86.1668-138.9231 | |
| 230 198 M | |
| 0 | |
| 0 | |
| 0.0219 | |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'NOVA',
Type:
'Common Stock',
Name:
'Novo Nordisk A/S',
Exchange:
'STU',
CurrencyCode:
'EUR',
CurrencyName:
'Euro',
CurrencySymbol:
'€',
CountryName:
'Germany',
CountryISO:
'DE',
OpenFigi:
NULL,
ISIN:
NULL,
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
NULL,
Industry:
NULL,
CUSIP:
NULL,
}
Novo Nordisk A/S Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Novo Nordisk A/S Earnings via APIs
- Latest Release 2024-11-06
- EPS/Forecast NaN
Get Novo Nordisk A/S End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Novo Nordisk A/S latest news via APIs
Novo Nordisk Slumps On Tightened Outlook As Wegovy Beats, But Ozempic Lags
Novo Nordisk stock fell Wednesday after the drugmaker's weight-loss drug beat forecasts, but Ozempic sales missed. Continue reading View comments
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
